GSK Leaves RDPAC; China’s Anti-Graft Efforts Gather Pace
This article was originally published in PharmAsia News
Executive Summary
GSK announced its withdrawal from RDPAC as the committee holds meetings in response to the pharma corruption crackdown, and Chinese authorities plan further measures.